Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
QLTI's Cash to Debt is ranked higher than
98% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. QLTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
QLTI' s Cash to Debt Range Over the Past 10 Years
Min: 0.7  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
QLTI's Interest Coverage is ranked higher than
98% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QLTI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
QLTI' s Interest Coverage Range Over the Past 10 Years
Min: 2.58  Med: 10000.00 Max: 9999.99
Current: No Debt
2.58
9999.99
F-Score: 2
Z-Score: 5.09
M-Score: -4.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -27.71
QLTI's ROE (%) is ranked higher than
52% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. QLTI: -27.71 )
Ranked among companies with meaningful ROE (%) only.
QLTI' s ROE (%) Range Over the Past 10 Years
Min: -45.67  Med: -6.58 Max: 51.71
Current: -27.71
-45.67
51.71
ROA (%) -26.78
QLTI's ROA (%) is ranked higher than
50% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. QLTI: -26.78 )
Ranked among companies with meaningful ROA (%) only.
QLTI' s ROA (%) Range Over the Past 10 Years
Min: -33.42  Med: -6.31 Max: 28.78
Current: -26.78
-33.42
28.78
ROC (Joel Greenblatt) (%) -4677.62
QLTI's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. QLTI: -4677.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
QLTI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -234.35  Med: -62.68 Max: 29.02
Current: -4677.62
-234.35
29.02
Revenue Growth (3Y)(%) -100.00
QLTI's Revenue Growth (3Y)(%) is ranked lower than
93% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. QLTI: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
QLTI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -8.65 Max: 268
Current: -100
-100
268
EBITDA Growth (3Y)(%) -50.20
QLTI's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. QLTI: -50.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
QLTI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.7  Med: -1.95 Max: 87.2
Current: -50.2
-60.7
87.2
EPS Growth (3Y)(%) -47.10
QLTI's EPS Growth (3Y)(%) is ranked lower than
90% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. QLTI: -47.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
QLTI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.1  Med: -4.35 Max: 84
Current: -47.1
-47.1
84
» QLTI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

QLTI Guru Trades in Q2 2015

Charles Brandes 153,280 sh (New)
Jim Simons 564,415 sh (+65.36%)
First Eagle Investment Sold Out
» More
Q3 2015

QLTI Guru Trades in Q3 2015

Charles Brandes 181,840 sh (+18.63%)
Jim Simons 376,764 sh (-33.25%)
» More
Q4 2015

QLTI Guru Trades in Q4 2015

Charles Brandes 224,071 sh (+23.22%)
Jim Simons 362,264 sh (-3.85%)
» More
Q1 2016

QLTI Guru Trades in Q1 2016

Charles Brandes 224,071 sh (unchged)
Jim Simons 101,623 sh (-71.95%)
» More
» Details

Insider Trades

Latest Guru Trades with QLTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XKRX:217950, TSE:4584, TSX:AUP, AMEX:ATNM, AMEX:PLX, ASX:ACR » details
Traded in other countries:QLT.Canada, QLT.Germany,
QLT Inc is a biotechnology company conducts development and commercialization of ocular products that address the unmet medical needs of patients and clinicians.

QLT Inc was formed in 1981 under the laws of the Province of British Columbia. It is a biotechnology company conducts development and commercialization of ocular products that address the unmet medical needs of patients and clinicians. The Company is developing QLT091001, a synthetic retinoid compound for the potential treatment of certain age-related and inherited retinal degenerative diseases. Its competitors include pharmaceutical and biopharmaceutical companies. The research and development, preclinical studies and clinical trials, and ultimately, the manufacturing, marketing and labelling of its products, are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries.

Ratios

vs
industry
vs
history
P/B 0.62
QLTI's P/B is ranked higher than
97% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. QLTI: 0.62 )
Ranked among companies with meaningful P/B only.
QLTI' s P/B Range Over the Past 10 Years
Min: 0.2  Med: 0.69 Max: 2.01
Current: 0.62
0.2
2.01
EV-to-EBIT 1.76
QLTI's EV-to-EBIT is ranked higher than
86% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. QLTI: 1.76 )
Ranked among companies with meaningful EV-to-EBIT only.
QLTI' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.5  Med: -1.00 Max: 4.2
Current: 1.76
-18.5
4.2
EV-to-EBITDA 1.79
QLTI's EV-to-EBITDA is ranked higher than
87% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. QLTI: 1.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
QLTI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.5  Med: -1.00 Max: 4.2
Current: 1.79
-19.5
4.2
Current Ratio 33.59
QLTI's Current Ratio is ranked higher than
96% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. QLTI: 33.59 )
Ranked among companies with meaningful Current Ratio only.
QLTI' s Current Ratio Range Over the Past 10 Years
Min: 1.1  Med: 19.39 Max: 85.25
Current: 33.59
1.1
85.25
Quick Ratio 33.59
QLTI's Quick Ratio is ranked higher than
96% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. QLTI: 33.59 )
Ranked among companies with meaningful Quick Ratio only.
QLTI' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 19.17 Max: 85.25
Current: 33.59
1.07
85.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.64
QLTI's Price/Net Cash is ranked higher than
99% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. QLTI: 0.64 )
Ranked among companies with meaningful Price/Net Cash only.
QLTI' s Price/Net Cash Range Over the Past 10 Years
Min: 0.64  Med: 3.08 Max: 64.25
Current: 0.64
0.64
64.25
Price/Net Current Asset Value 0.63
QLTI's Price/Net Current Asset Value is ranked higher than
99% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. QLTI: 0.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
QLTI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.35  Med: 2.18 Max: 21.25
Current: 0.63
0.35
21.25
Price/Tangible Book 0.62
QLTI's Price/Tangible Book is ranked higher than
98% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. QLTI: 0.62 )
Ranked among companies with meaningful Price/Tangible Book only.
QLTI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.27  Med: 1.74 Max: 17.87
Current: 0.62
0.27
17.87
Price/Projected FCF 9.47
QLTI's Price/Projected FCF is ranked lower than
72% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. QLTI: 9.47 )
Ranked among companies with meaningful Price/Projected FCF only.
QLTI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.21  Med: 1.37 Max: 200
Current: 9.47
0.21
200
Earnings Yield (Greenblatt) (%) 56.80
QLTI's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. QLTI: 56.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
QLTI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 24.1  Med: 44.40 Max: 8619.4
Current: 56.8
24.1
8619.4

More Statistics

EPS (TTM) $ -0.74
Beta0.25
Short Percentage of Float0.64%
52-Week Range $1.38 - 3.26
Shares Outstanding (Mil)52.83

Analyst Estimate

Dec16 Dec17
Revenue (Mil $)
EPS ($) -0.57 -0.61
EPS without NRI ($) -0.57 -0.61
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for QLTI

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX Aug 13 2012 
QLT Inc. Reports Operating Results (10-K) Mar 01 2011 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 3,000 Shares Nov 08 2010 
QLT Inc. Reports Operating Results (10-Q) Nov 03 2010 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 5,000 Shares Jun 23 2010 
QLT Inc. (QLTI) CFO Cameron Nelson buys 10,000 Shares Nov 10 2009 
QLT Inc. Reports Operating Results (10-Q) Nov 06 2009 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 10,000 Shares Nov 04 2009 
QLT Inc. Reports Operating Results (10-Q) Aug 06 2009 
100 Mile Diet Idea #1: QLT Inc -- a Cigar Butt with Legs? May 20 2009 

More From Other Websites
QLT INC/BC Financials May 13 2016
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 05 2016
QLT Inc. reports 1Q loss May 05 2016
QLT Inc. reports 1Q loss May 05 2016
QLT Announces First Quarter 2016 Results May 05 2016
QLT Announces First Quarter 2016 Results May 05 2016
QLT Cancels $20 Million Private Placement May 02 2016
QLT Terminates $20 Million Private Placement May 02 2016
QLT INC/BC Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events,... May 02 2016
QLT Terminates $20 Million Private Placement May 02 2016
QLT Inc. Completes Enrollment in its Natural History Study Apr 22 2016
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 22 2016
QLT Inc. Completes Enrollment in its Natural History Study Apr 22 2016
QLT INC/BC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition... Apr 11 2016
The Zacks Analyst Blog Highlights: QLT, Twitter, Aegerion Pharmaceuticals, Linn and Lenovo Group Apr 07 2016
5 Stocks Near 52-Week Lows But Still Worth Buying Apr 06 2016
QLT Announces Date of Special Distribution to Shareholders Apr 04 2016
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 04 2016
QLT Announces Date of Special Distribution to Shareholders Apr 04 2016
Small Cap Victories From Foundry Apr 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)